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Abstract
Background: Most currently known breast cancer predisposition genes play a role in DNA repair by homologous
recombination. Recent studies conducted on RAD51 paralogs, involved in the same DNA repair pathway, have
identified rare germline mutations conferring breast and/or ovarian cancer predisposition in the RAD51C, RAD51D
and XRCC2 genes. The present study analysed the five RAD51 paralogs (RAD51B, RAD51C, RAD51D, XRCC2, XRCC3) to
estimate their contribution to breast and ovarian cancer predisposition.
Methods: The study was conducted on 142 unrelated patients with breast and/or ovarian cancer either with early
onset or with a breast/ovarian cancer family history. Patients were referred to a French family cancer clinic and had
been previously tested negative for a BRCA1/2 mutation. Coding sequences of the five genes were analysed by EMMA
(Enhanced Mismatch Mutation Analysis). Detected variants were characterized by Sanger sequencing analysis.
Results: Three splicing mutations and two likely deleterious missense variants were identified: RAD51B c.452 + 3A > G,
RAD51C c.706-2A > G, RAD51C c.1026 + 5_1026 + 7del, RAD51B c.475C > T/p.Arg159Cys and XRCC3 c.448C > T/p.
Arg150Cys. No RAD51D and XRCC2 gene mutations were detected. These mutations and variants were detected in
families with both breast and ovarian cancers, except for the RAD51B c.475C > T/p.Arg159Cys variant that occurred in a
family with 3 breast cancer cases.
Conclusions: This study identified the first RAD51B mutation in a breast and ovarian cancer family and is the first
report of XRCC3 mutation analysis in breast and ovarian cancer. It confirms that RAD51 paralog mutations confer breast
and ovarian cancer predisposition and are rare events. In view of the low frequency of RAD51 paralog mutations,
international collaboration of family cancer clinics will be required to more accurately estimate their penetrance and
establish clinical guidelines in carrier individuals.
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Background
Breast cancer is currently the most common cancer and
the leading cause of cancer deaths in women worldwide
[1]. Abnormal familial aggregations fitting a model of
autosomal dominant breast cancer genetic predisposition
account for about 5% of cases [2]. BRCA1 and BRCA2
are the two major genes, but explain only about 20% of
inherited breast cancers [3-5]. About ten genes are
known to be involved in breast cancer predisposition, ei-
ther isolated or associated with other cancers, with vari-
able breast cancer risks. Approximately 50% of familial
breast cancers remain unresolved by any of these genes
after genetic testing [6].
Most currently known breast cancer predisposition genes
play a role in the repair of DNA double-strand breaks by
homologous recombination: BRCA1 and BRCA2, associ-
ated with a high risk of breast cancer, and BRIP1 and
PALB2, associated with a moderate risk [7-9]. While breast
cancer predisposition is conferred by mono-allelic germline
mutations in these genes, bi-allelic germline mutations in
BRCA2, BRIP1 and PALB2 result in Fanconi anaemia, an
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autosomal recessive inherited syndrome characterized by
multiple developmental abnormalities and predisposition to
various cancers [10-12].
Genetic studies were recently conducted on the RAD51
paralogs, involved in the same DNA repair pathway:
BRCA2 protein loads RAD51 monomers at DNA double-
strand break sites; RAD51 recruitment also depends on
the RAD51 paralog family [13]. Bi-allelic mutations
resulting in Fanconi anaemia were identified in RAD51C
and XRCC2 [14,15]. Mono-allelic germline mutations
conferring breast and ovarian cancer predisposition were
identified in RAD51C and RAD51D [16,17]. XRCC2 muta-
tions were then detected in breast cancer families but a
subsequent population-based study failed to confirm an
association between XRCC2 variants and breast cancer
risk [18,19]. Johnson et al. conducted a study on RAD51B
in breast cancer families and did not detect any mutations
[20]. The XRCC3 gene has not yet been studied.
In this study, we analysed the five RAD51 paralogs
(RAD51B, RAD51C, RAD51D, XRCC2, XRCC3) in 142
unrelated patients with breast and/or ovarian cancer
to estimate their contribution to breast and ovarian
cancer predisposition.
Methods
Patients
The study was conducted on 142 unrelated patients with
breast and/or ovarian cancer either with early onset or
with a breast/ovarian cancer family history. Patients had
been previously tested negative for a BRCA1/2 mutation,
selected either for a predisposition probability higher than
70% according to the Claus model [2] or for enrichment
in ovarian cancer cases: 87 patients (61%) had a personal
or family history of both breast and ovarian cancer, 10 pa-
tients (7%) had a personal or family history of ovarian
cancer only and 45 patients (32%) had a personal or fam-
ily history of breast cancer only (Table 1). All patients
attended a visit with a geneticist and a genetic counsellor
in a family cancer clinic, mostly at the Institut Curie,
Paris, France. Patients gave their informed consent for
genetic testing. The study was approved by the local Eth-
ics Committee in Institut Curie.
Genomic DNA analysis
Genomic DNA was extracted from 2 mL whole-blood
samples collected on EDTA with the Quickgene 610-L au-
tomated system (Fujifilm) according to the manufacturer’s
instructions. RAD51 paralog mutation screening was
performed on coding exons and exon-intron junctions by
multiplex PCR and Enhanced Mismatch Mutation Ana-
lysis (EMMA) [21] except for 2 RAD51B exons which
were analysed by simplex PCR and direct sequencing
(Additional file 1: Table S1 and Additional file 2: Table
S2). PCR products showing abnormal EMMA profiles
were analysed by sequencing on an ABI PRISM 3130XL
Genetic analyzer (Applied Biosystems).
mRNA analysis for RAD51C splicing mutations
RNA was extracted from lymphoblastoid cell lines using
TRIzol reagent according to the manufacturer’s instruc-
tions (Invitrogen). 2 μg of total RNA from each sample
was used for reverse transcription in a 40 μL reaction
using the GeneAmp RNA PCR Core kit according to
the manufacturer’s instructions (Applied Biosystems).
cDNA was amplified with forward and reverse primers
GCATTCAGCACCTTCAGCTT and CTTTCGGTCCCAATGAAAGA for
RAD51C exon 5 skipping, TGACCTGTCTCTTCGTACTCG and
for RAD51C exon 8 skipping.
RAD51B immunohistochemistry
For RAD51B immunostaining, 4-μm-thick paraffin sec-
tions were cut and mounted on glass slides (Superfrost+,
Menzel Glazer). Preparations were dried for one hour at
58°C, then overnight at 37°C. Sections were deparaffined
with toluene and rehydrated with ethanol. Preparations
were pretreated with citrate buffer (0.01 M citric acid
pH 6.0), and a heat-based antigen retrieval method was
used prior to incubations. Endogenous peroxidase was
blocked using 3% hydrogen peroxidase solution for 5 mi-
nutes. The primary anti-RAD51B antibody used (clone
NBP1-66539, dilution 1/200) was from Novus Biologicals.
Sections were incubated for 15 minutes at 22°C with the
primary antibody followed by staining with anti-rabbit
HRP antibody (Leica Biosystems) for 10 minutes. Sections
were then revealed in a diaminobenzidine solution for
15 minutes and stained with hematoxylin for 7 minutes.
Missense variants pathogenic prediction
Three bioinformatics tools were used for missense vari-
ants pathogenic prediction: Align-GVGD [22,23], SIFT
[24,25] and Polyphen-2 [26,27]. Multiple sequence
Table 1 Patient personal and family history of breast/
ovarian cancer
Personal and family history n (%)
Personal history
Ovarian adenocarcinoma before the age of 70 4 (3)
Breast adenocarcinoma and ovarian cancer 6 (4)
Breast adenocarcinoma before the age of 36 1 (1)
Family history*
2 ovarian cancer cases 81 (57)
2 breast cancer cases 36 (25)
3 breast cancer cases 8 (6)
1 breast cancer case and 1 ovarian cancer case 6 (4)
*Family history was defined in first- or second-degree relatives in the
same lineage.
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alignment (MSA) for Align-GVGD and SIFT analysis
was an alignment of protein sequences of 11 species:
Human (Homo sapiens), Chimpanzee (Pan troglodytes),
Macaque (Macaca mulatta), Mouse (Mus musculus),
Rabbit (Oryctolagus cuniculus), Dog (Canis familiaris), Cat
(Felis catus), Bovine (Bos taurus), Opossum (Monodelphis
domestica), Platypus (Ornithorynchus anatinus), Chicken
(Gallus gallus) and Frog (Xenopus tropicalis). Missense
variants were interpreted as likely deleterious if they
were classified as deleterious or probably damaging by the
three tools.
Statistical analysis
Frequencies of mutations and likely deleterious variants
were compared between the cases and two control sam-
ples from online databases: European-American controls
from Exome Variant Server [28] and European controls
from 1000 Genomes project [29]. In a first step the two
control sample variant frequencies were compared using
Fisher’s exact test in order to check there was no signifi-
cant difference. In a second step the control samples were
pooled and the overall control variant frequency was com-
pared with the case sample one, using Fisher’s exact test.
All the tests were two-sided, with a p-value of 0.05 consid-
ered significant. Computations were performed using the
XLSTAT-2013 software.
Results
Three splicing mutations and two likely deleterious mis-
sense variants were identified in these 142 patients:
RAD51B c.452 + 3A >G, RAD51C c.706-2A >G, RAD51C
c.1026 + 5_1026 + 7del, RAD51B c.475C > T/p.Arg159Cys
and XRCC3 c.448C > T/p.Arg150Cys (Table 2). No muta-
tion was detected in the RAD51D and XRCC2 genes (See
Additional file 3: Table S3 for all variants and polymor-
phisms detected in this study).
All variants detected on DNA were tested by in silico
splicing effect prediction according to a previously pub-
lished pipeline [30]: a greater than 15% decrease of the
MaxEntScan score for donor/acceptor splice sites and a
greater than 5% decrease of the SpliceSiteFinder-like score
for donor/acceptor splice sites were considered to be sig-
nificant with 96% sensitivity and 83% specificity. Three
variants were likely to alter splicing according to this pipe-
line: RAD51C c.706-2A >G and c.1026 + 5_1026 + 7del,
and RAD51B c.452 + 3A >G. Exon skipping was con-
firmed by mRNA analysis for the two RAD51C mutations
(Figure 1). No RNA was available to study the impact of
the RAD51B c.452 + 3A >G mutation but, using immuno-
histochemistry with anti-RAD51B antibody, loss of ex-
pression of RAD51B protein was observed in breast
carcinoma cells from the patient bearing this mutation, as
compared with that detected in the nucleus of normal
duct cells (Figure 2).
Likely deleterious missense variants reported in this
study in the RAD51B and XRCC3 genes are located in
the ATP-binding domain of the proteins and result in
the replacement of highly conserved amino acids with
subsequent high Grantham score (Table 2).
Mutations and likely deleterious variants were de-
tected in families with both breast and ovarian cancers,
except for the RAD51B p.Arg159Cys variant that oc-
curred in a family with 3 breast cancer cases (Figure 3).
The RAD51C c.706-2A > G mutation co-segregated with
an ovarian cancer at the age of 67 years for a paternal
aunt of the index case. No other co-segregation studies
have been performed to date.
Discussion
This study reports RAD51 paralog analysis in breast and
ovarian cancer cases. To our knowledge, this is the first
report of a RAD51B mutation and evaluation of the con-
tribution of the XRCC3 gene to breast and ovarian can-
cer predisposition.
RAD51B gene
We identified a RAD51B mutation and a likely deleteri-
ous variant in two patients: the RAD51B c.452 + 3A > G
mutation was detected in a breast and ovarian cancer
family case and the RAD51B p.Arg159Cys variant was
detected in a family with 3 breast cancer cases.
RAD51B has been previously evaluated as a candidate
gene for breast cancer predisposition but no mutation
was detected in a study of 188 multiple breast cancer fam-
ily cases (Johnson et al. [20]). The low frequency of
RAD51B mutations may account for the differences ob-
served between our results and those reported by Johnson
et al., as previously described for RAD51C, RAD51D and
XRCC2 [16-18]. More generally concerning RAD51B in-
volvement in cancer, previous studies have identified
chromosomal rearrangements disrupting RAD51B in be-
nign tumours, particularly uterine leiomyomas [31,32].
Overall, haploinsufficiency of RAD51B was shown to in-
duce genomic instability in human cells, suggesting its in-
volvement in cancer predisposition [33]. In addition, our
findings must be interpreted in the context of two
genome-wide association studies (GWAS) that identified
the minor allele of single nucleotide polymorphisms
(SNPs) in RAD51B acting as low risk factors for breast
cancer: rs999737 [34] and rs1314913 [35], located in
RAD51B introns 10 and 7, respectively. Overall, these
findings might indicate that RAD51B acts as a susceptibil-
ity factor or as a major gene depending on the context. In-
deed, it cannot be excluded that the minor allele of these
SNPs indirectly reflects a major influence of RAD51B
[36], as a recent study showed that high risk rare muta-
tions can account for some synthetic associations identi-
fied by GWAS [37].
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Table 2 Mutations and likely deleterious variants, their effect on splicing or protein, cancer history of carriers
Gene Genetic
variation
Variant class Effect on splicing Predicted effect on protein
(Align-GVGD class†)
Personal cancer
history (age at
diagnosis)
Family cancer history (age at diagnosis) Controls‡
RAD51B c.452 + 3A > G Splicing
mutation
Exon 5 skipping by
in silico prediction*
Unstable or truncated protein,
confirmed by negative IHC
BC (34) Paternal aunt, BC (58); 3rd degree relative, OC (29) -
RAD51B c.475C > T, p.
Arg159Cys
Likely
deleterious
missense variant
No predicted effect ATP-binding domain, highly
conserved amino acid, Grantham
180 (Class C65)
BC (54) Sister, BC (45); Sister’s daughter BC (45) 2/4299
RAD51C c.706-2A > G Splicing
mutation
Exon 5 skipping
confirmed by mRNA
analysis
44 amino acids loss in ATP-binding
domain
BC (39) Paternal aunt§, OC (67) -
RAD51C c.1026 +
5_1026 + 7del
Splicing
mutation
Exon 8 skipping
confirmed by mRNA
analysis
Unstable or truncated protein BC (38), OC (51) Father, PC (69); Paternal grandmother, UC (66); Paternal
grandfather, SC (69)
-
XRCC3 c.448C > T, p.
Arg150Cys
Likely
deleterious
missense variant
No predicted effect ATP-binding domain, highly
conserved amino acid, Grantham 180
(Class C65)
BC (63) Mother, OC (61); Maternal aunt, BC (55); Maternal aunt, BC
(73); Maternal aunt, BC (76); Maternal aunt, BC (63, 79)
1/4276
BC: Breast cancer, OC: Ovarian cancer, PC: Pancreas cancer, UC: Uterine cancer, SC: Stomach cancer.
*See text for details.
†Align-Grantham Variation Grantham Deviation (Align-GVGD) classes range from C0 to C65; C65 class variants are the most likely to interfere with protein function [22,23].
§This paternal aunt also carried the RAD51C c.706-2A > G mutation.
‡Frequency in controls in online databases: Exome Variant Server [28], dbSNP [38], 1000 Genomes [29]. The three splicing mutations have never been described. The 2 missense variants were reported only in Exome
Variant Server, in European-American populations. Their frequencies in European-American populations are reported in this table.
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RAD51B c.452 + 3A >G is a novel mutation. Several ar-
guments strongly support its causality: this variation is ab-
sent in the thousands of controls tested in online databases
(Exome Variant Server [28], dbSNP [38], 1000 Genomes
[29]); in silico prediction concluded this variation was likely
to result in an out-of-frame exon skipping leading to a
truncated or unstable protein; RAD51B immunohisto-
chemistry in breast carcinoma cells of the patient bearing
this variation showed a loss of expression of RAD51B.
The RAD51B p.Arg159Cys variant is reported in Exome
Variant Server: this variant was detected in 2 out of 4,299
controls in European-American populations. We consider
this variant to be a likely deleterious variant because it
occurs in a functional domain and results in replacement
of a highly conserved amino acid with subsequent high
Grantham score and Align-Grantham Variation Grantham
Deviation (Align-GVGD) maximum score (C65), and very
low frequencies are reported in Exome Variant Server. Its
Exon 5: wild type mRNA
RAD51C c.706-2A>GControl
Exon 4 Exon 5
Exon 7 Exons 8&9
RAD51C c.1026+5_1026+7delControl
Exon 7 Exon 8
A
B
Exon 6: mRNA with exon 5 skipping
Exon 4 Exons 5&6
Exon 8: wild type mRNA
Exon 9: mRNA with exon 8 skipping
Figure 1 mRNA analysis for RAD51C splicing mutations showing exon skipping. (A) Electropherograms of Sanger sequencing analysis for a
control sample with wild type RAD51C mRNA only (left) and for RAD51C c.706-2A > G mutation with two types of mRNA: wild type mRNA and
mRNA with exon 5 skipping (right). (B) Electropherograms of Sanger sequencing analysis for a control sample with wild type RAD51C mRNA only
(left) and for RAD51C c.1026 + 5_1026 + 7del mutation with two types of mRNA: wild type mRNA and mRNA with exon 8 skipping (right).
Figure 2 RAD51B immunohistochemistry in breast tissue of patient carrying the RAD51B c.452 + 3A > G mutation. A brown staining of
moderate intensity is observed in the nucleus of non tumor epithelial cells located in normal duct (ND) of the breast tissue. In comparison, no
significant staining is detected in the nucleus of invasive carcinoma cells (ICC).
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occurrence in controls could be explained by an incom-
plete penetrance.
Overall, for the RAD51B gene, one truncating mu-
tation and one likely deleterious variant were detected
in 2 out of 142 patients selected for enrichment in
breast/ovarian cancer cases. In online databases, one
truncating mutation and two likely deleterious variants
were detected in 4 out of 4,678 controls (Additional file
4: Table S4). Frequency of RAD51B variants was sig-
nificantly higher in cases (p = 0.012), which suggests
RAD51B variants are associated with breast/ovarian
cancer risks.
XRCC3 gene
The XRCC3 p.Arg150Cys variant was detected in a family
with 1 ovarian cancer and 5 breast cancer cases. Like the
RAD51B missense variant reported in this study, the
XRCC3 p.Arg150Cys variant is reported with a very low
frequency in Exome Variant Server (1 out of 4,276 con-
trols in European-American populations). We consider
this variant to be a likely deleterious variant because it oc-
curs in a functional domain and results in replacement of
a highly conserved amino acid with subsequent high
Grantham score and Align-GVGD maximum score (C65).
This study is the first report of XRCC3 mutation screen-
ing in breast and ovarian cancer predisposition. Numer-
ous association studies have evaluated XRCC3 SNPs as
candidate risk factors for breast cancer, but the results of
these studies remain controversial. A recent meta-analysis
suggested that the minor allele of XRCC3 p.Thr241Met
SNP was a low risk factor and XRCC3 IVS5-14A >G SNP
a low protective factor for breast cancer [39].
RAD51C gene
Several studies have reported RAD51C causal mutations
in breast and ovarian cancer predisposition [16,40,41].
Two novel RAD51C splicing mutations are reported in
this study: RAD51C c.1026 + 5_1026 + 7del mutation is
truncating, resulting in an out-of-frame exon 8 skipping
and RAD51C c.706-2A > G mutation leads to the loss of
44 amino acids in a functional domain of the protein by
an in-frame exon 5 skipping. These two RAD51C muta-
tions were detected in families with both breast and
ovarian cancer cases, which is consistent with previous
studies. As this set of patients was enriched with ovarian
cancer cases and due to the low frequency of RAD51C
mutations, other studies must be conducted in larger
series to evaluate whether RAD51C confers predispos-
ition to ovarian cancer alone or to both breast and ovar-
ian cancer, which remains controversial [42].
Conclusions
This study identified the first RAD51B mutation in a
breast and ovarian cancer family and confirmed that
RAD51 paralog mutations confer breast and ovarian
cancer predisposition and are rare events. Identification
c.452+3A>G
RAD51B
c.475C>T/p.Arg159Cys
RAD51C
c.706-2A>G c.1026+5_1026+4del
c.448C>T/p.Arg150Cys
XRCC3
Figure 3 Pedigrees for RAD51 paralog mutation and likely causal variant carriers. Individuals with breast cancer (BC) are shown as red
circles, ovarian cancer (OC) as purple circles, and other cancers as blue circles. SC: stomach cancer; UC: uterine cancer; PC: pancreas cancer.
Disease and age in years at diagnosis are given underneath the symbol. The index case is indicated with an arrow. No co-segregation studies
have yet been performed, except for RAD51C c.706-2A > G: tested relative with OC carried the mutation, indicated by (+).
Golmard et al. BMC Cancer 2013, 13:484 Page 6 of 8
http://www.biomedcentral.com/1471-2407/13/484
of families with mutations in the RAD51B, RAD51C or
XRCC3 genes and genetic testing of family members
could be used to estimate the associated breast and ovar-
ian cancer risks. In view of the low frequency of RAD51
paralog mutations, international collaboration of family
cancer clinics will be required to more accurately esti-
mate their penetrance and establish clinical guidelines.
Such studies would be facilitated by the development of
Next Generation Sequencing allowing laboratories to
simultaneously analyse numerous genes.
Additional files
Additional file 1: Table S1. Multiplex PCR mixes.
Additional file 2: Table S2. Primers.
Additional file 3: Table S3. All variants and polymorphisms detected in
this study.
Additional file 4: Table S4. RAD51B variants in cases and controls.
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